Pfizer-Allergan merger raises questions about future of NuMedii deal

Speculation about the fallout from Pfizer ($PFE) and Allergan's ($AGN) $160 billion megamerger has begun. The San Francisco Business Times put together a list of companies that could be affected by the deal that includes NuMedii, the digital drug discovery player that struck a collaboration with Allergan in September. Article

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.